Gaithersburg-based biotech MedImmune and a division of 3M unveiled plans Friday to work together on a next-generation cancer immunotherapy drug.
Under the agreement, MedImmune — the biologics research and development arm of U.K. pharmaceutical giant AstraZeneca (NYSE: AZN) – licensed an agent called MEDI9197 from 3M Drug Delivery Systems. 3M said it developed the molecule as an injectable treatment for head and neck cancer that stimulates the body’s immune system to attack and destroy tumors.
{iframe}http://www.bizjournals.com/washington/blog/2015/09/medimmune-3m-ink-deal-on-next-gen-cancer.html?ana=e_du_pap&s=article_du&ed=2015-09-25&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1443461571{/iframe}